CHICAGO — When treating patients with type 2 diabetes, physicians may have more success if they use simultaneous combination therapy immediately rather than following the traditional stepped-up method of waiting to intensify treatment, according to a speaker at the Cardiometabolic Health Congress.
“I do believe that initial combination therapy with metformin plus a SGLT2 inhibitor or a GLP-1 receptor agonist may become the preferred standard therapy in newly diagnosed type 2 diabetes right from the outset,” Julio Rosenstock, MD, director of the Dallas Diabetes Research Center at Medical City and clinical professor of medicine at the University of Texas Southwestern Medical Center in Dallas, said during a presentation.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.